Reaktion #155

ord-bd19c64fd71c4dc0a1f39c0c85d4d230

Reaktionsgleichung

Brc1ccc(CN2CCOCC2)cc1
Brc1ccc(CN2CCOCC2)cc
Cc1ncc(-c2nc(N)ncc2F)n1C1CCOCC1
Cc1ncc(-c2nc(N)ncc2F
Cc1ncc(-c2nc(Nc3ccc(CN4CCOCC4)cc3)ncc2F)n1C1CCOCC1
Cc1ncc(-c2nc(Nc3ccc(

Lösungsmittel

Reaktionsbedingungen

Temperatur
90°CELSIUS

Vorschrift

The aim of the reaction is only optimization and test. The reaction described below was carried out under argon atmosphere. Palladium(II) acetate (2.245 mg, 10.00 µmol) and (R)-(-)-1-[(S)-2-(Dicyclohexylphosphino)ferrocenyl]ethyldi-t-butylphosphine (5.61 mg, 10.00 µmol) were mixed in DME (0.2 mL) in a 1.4 ml vial under argon and stirred for 1 minute at room temperature. The orange pre-mixed Pd-catalyst solution were added to a 10 mL Schlenk-tube containing 4-(4-bromobenzyl)morpholine (0.282 g, 1.1 mmol) and Sodium tert- pentoxide (0.161 g, 1.46 mmol) in DME (1.5 mL). Finally, 5-fluoro-4-(2-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine (0.277 g, 1 mmol) was added and the bright orange reaction mixture was stirred at 90 °C. The mixture turned from bright orange into bright yellow in 1 h. The reaction was followed by HPLC. No reaction took place, hence the mixture was discarded.

Quelle

750 AstraZeneca ELN dataset